San Diego, California 92161


Purpose:

This project will utilize a novel behavioral intervention for hoarding disorder that takes into account age and neurocognitive factors. The goal of this project is to gain knowledge on how treatment components may or may not work for Veterans with hoarding disorder. Further, the investigators hope to increase understanding of functional and long term outcomes in response to hoarding treatment.


Study summary:

Objective: The investigators propose to conduct a randomized controlled trial comparing six months (26 sessions) of Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) treatment to a robust comparator, six months of Exposure Therapy alone, in 136 participants with HD. Research Design: Assessments will be administered at baseline, during treatment (sessions 7, 13, 21), post-treatment, and 3- and 6-month follow-up, thus, all participants will be enrolled for one year. Methodology: The primary objective is to evaluate whether CREST significantly reduces hoarding symptoms and improves functional capacity and quality of life when compared to exposure therapy alone. The investigators will also examine the impact of treatment mediators; treatment adherence, changes in executive functioning, avoidance, symptom severity on outcomes. Age and executive functioning will also be explored as potential moderators. Finally, by repeatedly measuring treatment targets, the investigators will examine time to maximum treatment effect in an effort to understand mechanisms of change. Clinical Relationships: By providing a treatment for many Veterans with HD, the investigators can alter the course of their symptom trajectory and negative consequences, resulting in both healthcare costs savings and improved quality of life for Veterans.


Criteria:

Inclusion Criteria: - Veterans age 18-85 - Hoarding Disorder diagnosis outlined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)6 as measured by the Structured Interview for Hoarding Disorder (SIHD)67 - HD as a primary diagnosis - Stable on medications for at least 12 weeks, with no pharmacologic changes expected or made during the 12-month study - Voluntary consent to participate Exclusion Criteria: - Diagnosis of: - psychotic disorder - substance abuse disorder as measured by the Mini-International Neuropsychiatric Interview (M.I.N.I.)68 - Current or history of any neurodegenerative disease - Active suicidal ideation - Concurrent participation in psychotherapy or ET for HD, or prior history of CREST for HD


NCT ID:

NCT02402647


Primary Contact:

Principal Investigator
Catherine R Ayers, PhD
VA San Diego Healthcare System, San Diego, CA

Catherine R Ayers, PhD
Phone: (858) 642-2976
Email: Catherine.Ayers1@va.gov


Backup Contact:

Email: mary.dozier2@va.gov
Mary E Dozier, MS
Phone: (858) 642-1251


Location Contact:

San Diego, California 92161
United States

Catherine R Ayers, PhD
Phone: 858-642-2976
Email: Catherine.Ayers1@va.gov

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.